Skip to main content
Premium Trial:

Request an Annual Quote

MRSA Dx Sales Help Drive 37 Percent Jump in Cepheid's Q2 Revenues

NEW YORK (GenomeWeb News) — Cepheid today said second-quarter revenues increased 37 percent as R&D spending rose 28 percent and net loss declined around 26 percent.
 
Total receipts for the three months ended June 30 increased to $27.2 million from $19.8 million year over year. This included $23.6 million of total product sales, which increased 25 percent to from $18.9 million for the second quarter 2006.
 
The company attributed the increase in product sales to a 165 percent increase in clinical product sales and a 43 percent increase in industrial sales, offset slightly by a 26 percent decrease in biothreat sales, compared to the year-ago period.
 
"The increase in clinical product sales during the second quarter reflects growing market traction for on-demand molecular diagnostics, particularly with the adoption of the Xpert [methicillin-resistant Staphylococcus aureus] test,” Cepheid CEO John Bishop said in a statement.
 
The company said the decrease in its biothreat business was due to a planned reduction in the price of Cepheid’s Anthrax cartridges to the United States Postal Service that is linked to a five-year agreement that the company is currently negotiating with USPS.
 
Instrument sales rose around 133 percent to $9.4 million; reagent and disposable sales decreased 5 percent to $14.2 million; contract revenues rose 180 percent to $1.9 million; and government and government-sponsored research revenue soared more than five-fold to $1.7 million.
 
R&D spending rose to $7.4 million from $5.8 million year over year.
 
Net loss fell to $5.2 million from $7 million in the year-ago period.
 
Cepheid said it had around $7.2 million in cash and cash equivalents, and $38.3 million in marketable securities at the end of the second quarter.
 
The company expects total revenue for the full year to be between $117 million and $123 million.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.